Iraqi Board Clinical Pharmacy key terms

The apparent volume relating the amount of drug in the body to its plasma concentration. It estimates how extensively a drug distributes into tissues and helps calculate a loading dose.

The volume of plasma from which a drug is completely removed per unit time. It determines the maintenance dose rate needed to sustain a target steady-state concentration.

The condition in which drug input equals drug elimination, so plasma concentrations remain stable over a dosing interval. It is generally reached after four to five half-lives of regular dosing.

The time required for the plasma concentration to fall by half. It guides dosing interval selection and estimates how long a drug persists after therapy is stopped or a steady state is achieved.

An initial larger dose given to reach a target concentration quickly rather than waiting several half-lives. It is calculated from volume of distribution and desired concentration, independent of clearance.

Measurement of drug concentrations in blood to individualize dosing for drugs with narrow therapeutic indices or unpredictable pharmacokinetics. Correct sampling time relative to the dose is essential for valid interpretation.

A property of drugs whose effective and toxic concentrations lie close together, so small pharmacokinetic changes risk toxicity or failure. Such drugs typically require careful dosing and often therapeutic drug monitoring.

Presystemic elimination of an orally administered drug during absorption and passage through the gut wall and liver before reaching systemic circulation. It reduces oral bioavailability and can be saturated at higher doses.

The fraction of an administered dose that reaches systemic circulation unchanged. Intravenous dosing defines complete bioavailability, while oral values reflect absorption and first-pass losses.

Elimination at a constant rate independent of concentration, occurring when metabolic or transport pathways are saturated. Small dose increases can then produce disproportionate rises in plasma concentration and toxicity.

Elimination in which a constant fraction of the drug is removed per unit time, so the rate falls as concentration falls. Most drugs follow this pattern and show a fixed half-life.

A reduced response to a drug after repeated exposure, caused by receptor downregulation, desensitization, or compensatory adaptations. It differs from pharmacokinetic tolerance, where metabolism or clearance increases.

A ligand that binds a receptor without activating it and blocks the effect of agonists. Competitive antagonists shift the agonist dose-response curve rightward, while noncompetitive antagonists reduce the maximal response.

A drug that binds and activates a receptor but produces less than the maximal response of a full agonist. It can act as a functional antagonist when competing with a full agonist at the same receptor.

A ratio comparing the dose producing toxicity with the dose producing the desired effect. A low value signals a small safety margin and greater need for monitoring and cautious titration.

An estimate of glomerular filtration rate derived from serum creatinine, age, sex, and weight. It is used to adjust doses of renally eliminated drugs and to stage kidney function.

An abrupt decline in kidney function marked by rising serum creatinine or falling urine output. Causes are classified as prerenal, intrinsic renal, or postrenal, and drug therapy must be reviewed for nephrotoxins.

A syndrome of impaired systolic function with ejection fraction typically below 40 percent. Guideline therapy combines renin-angiotensin system inhibition, beta-blockade, mineralocorticoid receptor antagonism, and SGLT2 inhibition.

A drug blocking the renin-angiotensin-aldosterone system, such as an ACE inhibitor, angiotensin receptor blocker, or mineralocorticoid receptor antagonist. These agents lower blood pressure and improve outcomes in heart failure and kidney disease.

An agent inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb, producing potent diuresis. It relieves congestion in heart failure and edema but can cause hypokalemia and volume depletion.

Serum potassium above the normal range, risking cardiac arrhythmia and muscle weakness. Drugs such as RAAS inhibitors, potassium-sparing diuretics, and trimethoprim commonly contribute and require monitoring.

A coordinated program promoting appropriate antimicrobial selection, dose, duration, and route to improve outcomes and limit resistance and toxicity. Core activities include prospective audit, formulary restriction, and de-escalation.

The lowest antimicrobial concentration that prevents visible growth of a bacterial isolate under standardized conditions. It guides susceptibility interpretation and dosing decisions for concentration-dependent or time-dependent drugs.

A pattern in which antimicrobial efficacy depends mainly on the fraction of the dosing interval that free drug concentration exceeds the MIC. Beta-lactams are classic examples, supporting extended or continuous infusions.

A pattern in which the peak concentration relative to the MIC drives bacterial killing. Aminoglycosides illustrate this, supporting large once-daily doses that maximize peak while limiting trough exposure.

Narrowing empiric antimicrobial therapy once culture and susceptibility results are available, or stopping unnecessary agents. It reduces resistance selection, adverse effects, and cost without compromising outcomes.

Antimicrobial treatment started before the causative organism and susceptibility are known, based on the likely pathogens and site of infection. It is later refined using culture results.

A marker reflecting average blood glucose over roughly the preceding two to three months. It is used to diagnose and monitor diabetes, though hemoglobinopathies and anemia can distort results.

Abnormally low blood glucose, typically below 70 mg/dL, causing sweating, tremor, confusion, and potentially seizures. It is a common adverse effect of insulin and sulfonylureas requiring prompt carbohydrate treatment.

A cluster of central obesity, dyslipidemia, hypertension, and impaired glucose regulation that raises cardiovascular and diabetes risk. Management emphasizes lifestyle change and treating each component.

A synthetic thyroxine replacement used for hypothyroidism. Absorption is reduced by food, calcium, and iron, so it is taken on an empty stomach and monitored with thyroid-stimulating hormone levels.

Use of HMG-CoA reductase inhibitors to lower LDL cholesterol and reduce cardiovascular events. Monitoring includes lipid panels and awareness of myopathy and hepatic enzyme elevation.

An anti-inflammatory controller therapy for asthma and some chronic obstructive pulmonary disease regimens. Patients must rinse the mouth after use to reduce oral candidiasis and should use it regularly rather than as rescue therapy.

A bronchodilator providing rapid relief of bronchospasm, used as needed for acute asthma symptoms. Increasing reliance on it signals inadequate control and need to step up controller therapy.

The maximum speed of forced expiration, measured with a portable meter. Serial readings help patients and clinicians detect worsening airway obstruction before severe exacerbation occurs.

A drug irreversibly inhibiting the gastric proton pump, suppressing acid secretion for gastroesophageal reflux and peptic ulcer disease. Long-term use is associated with infection, nutrient deficiency, and fracture risk.

Combination therapy, usually a PPI plus two or more antibiotics, given for a defined course to clear gastric H. pylori infection. Adherence and local resistance patterns strongly influence cure rates.

Hepatic damage caused by a medication or its metabolite, ranging from asymptomatic enzyme elevation to acute failure. Causality assessment requires temporal relationship, exclusion of alternatives, and recognition of known hepatotoxins.

A potentially life-threatening toxicity from serotonergic drugs, marked by agitation, autonomic instability, tremor, clonus, and hyperthermia. It requires stopping offending agents and supportive care, sometimes with cyproheptadine.

Switching from one opioid to another to improve analgesia or limit toxicity, using equianalgesic dose conversions. Incomplete cross-tolerance means the calculated dose is usually reduced and then titrated.

Fever in a patient with severe neutropenia, a medical emergency requiring prompt empiric broad-spectrum antibiotics. Delay in treatment increases mortality from gram-negative bacteremia.

A metabolic emergency from rapid cancer cell breakdown, causing hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Prevention includes hydration, allopurinol or rasburicase, and close electrolyte monitoring.

A common transfusion reaction with fever and chills without red cell destruction. It is managed by stopping the transfusion, supportive care, and future use of leukoreduced products.

A harmful or unintended response to a medicine at normal doses. Detection, documentation, and reporting to pharmacovigilance systems underpin medication safety.

A structured questionnaire scoring the likelihood that a drug caused an adverse event. It considers temporal sequence, dechallenge and rechallenge, alternative causes, and prior reports.

The science of detecting, assessing, understanding, and preventing adverse effects of medicines. Activities include spontaneous reporting, signal detection, and risk management after marketing.

A structured process of comparing a patient's current medicines with newly prescribed ones at transitions of care. It reduces omissions, duplications, and dosing errors.

A drug carrying heightened risk of significant harm when used incorrectly, such as insulin, anticoagulants, and concentrated electrolytes. Special safeguards include independent double checks and standardized storage.

The number of patients who must receive an intervention for one additional patient to benefit. It is the reciprocal of absolute risk reduction and helps express clinical usefulness.

The ratio of event risk in the exposed group to that in the unexposed group. It indicates strength of association but can overstate clinical impact when baseline risk is low.

The ratio of odds of an event in one group to the odds in another, commonly used in case-control studies. It approximates relative risk only when the outcome is rare.

A range of values likely to contain the true effect estimate, with a stated probability such as 95 percent. Narrower intervals indicate greater precision and help judge statistical significance.

A patient's voluntary agreement to treatment after receiving adequate information about benefits, risks, and alternatives. It respects autonomy and is a core ethical and legal requirement in pharmacy practice.

Any preventable event that may cause or lead to inappropriate medication use or patient harm. Errors occur in prescribing, dispensing, administration, and monitoring stages and are addressed through system safeguards.